ESMO 2024: Hope and Disappointment for Ovarian Cancer Treatment

At this year’s ESMO congress, the long-awaited final overall survival in patients with newly diagnosed advanced ovarian cancer treated with the parp-inhibitor niraparib as first-line maintenance therapy was presented. In this MEDtalk, Mansoor Raza Mirza from Rigshospitalet, Copenhagen University Hospital, Denmark, presented the results of the PRIMA trial. He also perspectives the status of treatment of ovarian cancer with immunotherapy.